8-KLeadership ChangesOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Feb 21, 2017)

Filed February 21, 2017For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb (BMY) announced two significant corporate actions via an 8-K filing on February 21, 2017. Firstly, the company temporarily expanded its Board of Directors by three members: Robert J. Bertolini, Matthew W. Emmens, and Theodore R. Samuels, who were deemed independent. This expansion is temporary until the 2017 annual meeting of stockholders, after which the Board will return to eleven directors, with these three nominees standing for election. This move likely aims to bring in new expertise or perspectives to the board. Secondly, and of potentially greater immediate financial impact for investors, BMY entered into accelerated share repurchase (ASR) agreements totaling $2.0 billion. These agreements, executed with Morgan Stanley & Co. LLC and Goldman, Sachs & Co., are part of the company's existing share repurchase authorization. The majority of the shares are expected to be received by the end of February 2017, with final settlement anticipated by the end of Q2 2017. The ASR program signifies a strong commitment from management to return capital to shareholders and indicates confidence in the company's financial health and future prospects.

Key Highlights

  • 1Bristol-Myers Squibb (BMY) temporarily expanded its Board of Directors from eleven to fourteen members.
  • 2Three new independent directors, Robert J. Bertolini, Matthew W. Emmens, and Theodore R. Samuels, were appointed.
  • 3The board expansion is temporary and will revert to eleven directors at the 2017 annual meeting, with the new directors standing for election.
  • 4BMY entered into accelerated share repurchase (ASR) agreements totaling $2.0 billion.
  • 5The ASR agreements are with Morgan Stanley & Co. LLC and Goldman, Sachs & Co.
  • 6Approximately 80% of the repurchased shares are expected to be received by February 28, 2017.
  • 7The ASR program is consistent with the company's existing share repurchase authorization announced in October 2016.

Frequently Asked Questions

The primary financial significance lies in the announcement of $2.0 billion in accelerated share repurchase (ASR) agreements. This action demonstrates the company's commitment to returning capital to shareholders and suggests management's confidence in the company's financial position and stock valuation.

The filing indicates the temporary expansion was to fill newly created directorships with three independent directors. While specific strategic reasons are not detailed, such expansions can be to bring in new expertise, broaden governance perspectives, or prepare for future strategic initiatives. The temporary nature and stated intention to return to eleven directors suggest a planned adjustment rather than a permanent increase in board size.

Approximately 80% of the shares are expected to be repurchased and received by the company on February 28, 2017. The final settlement of the entire $2.0 billion repurchase program is anticipated to be completed before the end of the second quarter of 2017.

The newly appointed directors, Messrs. Bertolini, Emmens, and Samuels, were appointed to serve until the 2017 annual meeting of stockholders. At that meeting, they will stand for election along with eleven other directors, at which point the Board's size will return to eleven members. Their long-term tenure depends on successful election by shareholders.